196 related articles for article (PubMed ID: 15812545)
1. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels WS
Br J Cancer; 2005 Apr; 92(8):1421-9. PubMed ID: 15812545
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
3. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
4. Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants.
Heurtault B; Thomann JS; Jedrzejewska J; Wels WS; Schuber F; Frisch B
J Liposome Res; 2006; 16(3):205-13. PubMed ID: 16952875
[TBL] [Abstract][Full Text] [Related]
5. Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes.
Boeckler C; Dautel D; Schelté P; Frisch B; Wachsmann D; Klein JP; Schuber F
Eur J Immunol; 1999 Jul; 29(7):2297-308. PubMed ID: 10427993
[TBL] [Abstract][Full Text] [Related]
6. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR
J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792
[TBL] [Abstract][Full Text] [Related]
7. Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus-derived peptides and confers sterile immunity.
Takagi A; Kobayashi N; Taneichi M; Uchida T; Akatsuka T
Biochem Biophys Res Commun; 2013 Jan; 430(1):183-9. PubMed ID: 23159619
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
Rohrbach F; Weth R; Kursar M; Sloots A; Mittrücker HW; Wels WS
J Immunol; 2005 May; 174(9):5481-9. PubMed ID: 15843546
[TBL] [Abstract][Full Text] [Related]
9. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
10. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer.
Naghibi L; Yazdani M; Momtazi-Borojeni AA; Razazan A; Shariat S; Mansourian M; Arab A; Barati N; Arabsalmani M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR
PLoS One; 2020; 15(12):e0243550. PubMed ID: 33301467
[TBL] [Abstract][Full Text] [Related]
11. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP
Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863
[TBL] [Abstract][Full Text] [Related]
12. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
13. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus.
Hiranuma K; Tamaki S; Nishimura Y; Kusuki S; Isogawa M; Kim G; Kaito M; Kuribayashi K; Adachi Y; Yasutomi Y
J Gen Virol; 1999 Jan; 80 ( Pt 1)():187-193. PubMed ID: 9934701
[TBL] [Abstract][Full Text] [Related]
14. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
15. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
16. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
Cho HI; Niu G; Bradley N; Celis E
Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
[TBL] [Abstract][Full Text] [Related]
17. Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine.
Wang L; Miyahara Y; Kato T; Wang L; Aota T; Kuribayashi K; Shiku H
Cancer Immun; 2003 Nov; 3():16. PubMed ID: 14629132
[TBL] [Abstract][Full Text] [Related]
18. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
Burkhardt UE; Sloots A; Jakobi V; Wei WZ; Cavallo F; Kloke BP; Wels WS
Cancer Immunol Immunother; 2012 Sep; 61(9):1473-84. PubMed ID: 22331080
[TBL] [Abstract][Full Text] [Related]
19. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
20. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
